{"id":"W4245954238","doi":"10.1016/s0305-7372(04)00144-6","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆, ☆, ☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Oncology; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Cancer research; Cancer; Cisplatin; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004826511,0.001387696,0.002984179,0.000421349,0.0001868171,0.0001476004,0.0001934391,0.0002904957,0.0001201707],"category_scores_gemma":[0.00002701894,0.0009148053,0.000173022,0.000848204,0.0001703287,0.0006777824,0.00005063995,0.0007451304,0.000001428341],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003872607,"about_ca_system_score_gemma":0.002441125,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.06950875,"about_ca_topic_score_gemma":0.2054941,"domain_scores_codex":[0.9947036,0.0002620396,0.00164301,0.001834067,0.0005296123,0.00102769],"domain_scores_gemma":[0.9968531,0.0003357345,0.001305066,0.0007868326,0.0002459601,0.0004732996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1718984,0.01678753,0.6023797,0.003278898,0.00255928,0.0007220762,0.03302985,0.003324839,0.0173463,0.00003616314,0.0002073632,0.1484296],"study_design_scores_gemma":[0.8654392,0.014982,0.08783597,0.01102517,0.002659302,0.00001444388,0.00260397,0.001336012,0.008946413,0.00002360711,0.002970841,0.002163021],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9491799,0.02785845,0.0001099059,0.002834768,0.000363783,0.01824665,0.0008835855,0.00007442847,0.0004484856],"genre_scores_gemma":[0.9181156,0.05876117,0.004021934,0.001199351,0.0001640319,0.01590456,0.000907512,0.0002269556,0.0006988614],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6935409,"threshold_uncertainty_score":0.9999514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01387739812871515,"score_gpt":0.3274173636403254,"score_spread":0.3135399655116102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}